Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

RGC-32 and diseases: the first 20 years.

Vlaicu SI, Tatomir A, Anselmo F, Boodhoo D, Chira R, Rus V, Rus H.

Immunol Res. 2019 Jun 27. doi: 10.1007/s12026-019-09080-0. [Epub ahead of print] Review.

PMID:
31250246
2.

Role of C5b-9 and RGC-32 in Cancer.

Vlaicu SI, Tatomir A, Rus V, Rus H.

Front Immunol. 2019 May 9;10:1054. doi: 10.3389/fimmu.2019.01054. eCollection 2019. Review.

3.

Letter by Rus et al Regarding Article, "RGC-32 (Response Gene to Complement 32) Deficiency Protects Endothelial Cells From Inflammation and Attenuates Atherosclerosis".

Rus H, Talpos-Caia A, Tatomir A, Vlaicu SI.

Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):e96. doi: 10.1161/ATVBAHA.118.311140. No abstract available.

PMID:
29793993
4.

Lack of Evidence for Racial Disparity in 30-Day All-Cause Readmission Rate for Older US Veterans Hospitalized with Heart Failure.

Kheirbek RE, Wojtusiak J, Vlaicu SO, Alemi F.

Qual Manag Health Care. 2016 Oct/Dec;25(4):191-196.

PMID:
27749715
5.

RGC-32 is expressed in the human atherosclerotic arterial wall: Role in C5b-9-induced cell proliferation and migration.

Vlaicu SI, Tatomir A, Boodhoo D, Ito T, Fosbrink M, Cudrici C, Mekala AP, Ciriello J, Crişan D, Boţan E, Rus V, Rus H.

Exp Mol Pathol. 2016 Oct;101(2):221-230. doi: 10.1016/j.yexmp.2016.09.004. Epub 2016 Sep 13.

PMID:
27619159
6.

The role of complement system in adipose tissue-related inflammation.

Vlaicu SI, Tatomir A, Boodhoo D, Vesa S, Mircea PA, Rus H.

Immunol Res. 2016 Jun;64(3):653-64. doi: 10.1007/s12026-015-8783-5. Review.

PMID:
26754764
7.

The role of complement activation in atherogenesis: the first 40 years.

Vlaicu SI, Tatomir A, Rus V, Mekala AP, Mircea PA, Niculescu F, Rus H.

Immunol Res. 2016 Feb;64(1):1-13. doi: 10.1007/s12026-015-8669-6. Review.

PMID:
26091721
8.

RGC-32 is a novel regulator of the T-lymphocyte cell cycle.

Tegla CA, Cudrici CD, Nguyen V, Danoff J, Kruszewski AM, Boodhoo D, Mekala AP, Vlaicu SI, Chen C, Rus V, Badea TC, Rus H.

Exp Mol Pathol. 2015 Jun;98(3):328-37. doi: 10.1016/j.yexmp.2015.03.011. Epub 2015 Mar 11.

9.

SIRT1 is decreased during relapses in patients with multiple sclerosis.

Tegla CA, Azimzadeh P, Andrian-Albescu M, Martin A, Cudrici CD, Trippe R 3rd, Sugarman A, Chen H, Boodhoo D, Vlaicu SI, Royal W 3rd, Bever C, Rus V, Rus H.

Exp Mol Pathol. 2014 Apr;96(2):139-48. doi: 10.1016/j.yexmp.2013.12.010. Epub 2014 Jan 5.

PMID:
24397908
10.

Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Vlaicu SI, Tegla CA, Cudrici CD, Danoff J, Madani H, Sugarman A, Niculescu F, Mircea PA, Rus V, Rus H.

Immunol Res. 2013 May;56(1):109-21. doi: 10.1007/s12026-012-8381-8. Review.

PMID:
23247987
11.

Eating habits in an adolescent population from Timiş county.

Ursoniu S, Vernic C, Vlaicu B, Petrescu C, Fira-Mladinescu C, Putnoky S, Suciu O, Fira-Mladinescu O, Vlaicu S.

Rev Med Chir Soc Med Nat Iasi. 2010 Oct-Dec;114(4):1155-61.

PMID:
21495459
12.

Epigenetic modifications induced by RGC-32 in colon cancer.

Vlaicu SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, Azimzadeh P, Rus V, Chen H, Mircea PA, Shamsuddin A, Rus H.

Exp Mol Pathol. 2010 Feb;88(1):67-76. doi: 10.1016/j.yexmp.2009.10.010. Epub 2009 Oct 31.

13.

Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.

Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu S, Singh A, Rus H.

J Neuroimmunol. 2009 Aug 18;213(1-2):3-11. doi: 10.1016/j.jneuroim.2009.06.006. Epub 2009 Jul 4. Review.

14.

Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.

Fosbrink M, Cudrici C, Tegla CA, Soloviova K, Ito T, Vlaicu S, Rus V, Niculescu F, Rus H.

Exp Mol Pathol. 2009 Apr;86(2):87-94. doi: 10.1016/j.yexmp.2008.12.005. Epub 2009 Jan 7.

15.

Current Canadian initiatives to reimburse live organ donors for their non-medical expenses.

Vlaicu S, Klarenbach S, Yang RC, Dempster T, Garg AX.

Can J Public Health. 2007 Nov-Dec;98(6):481-3.

PMID:
19039887
16.

Role of response gene to complement 32 in diseases.

Vlaicu SI, Cudrici C, Ito T, Fosbrink M, Tegla CA, Rus V, Mircea PA, Rus H.

Arch Immunol Ther Exp (Warsz). 2008 Mar-Apr;56(2):115-22. doi: 10.1007/s00005-008-0016-3. Epub 2008 Mar 31.

PMID:
18373239
17.

Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis.

Cudrici C, Ito T, Zafranskaia E, Niculescu F, Mullen KM, Vlaicu S, Judge SI, Calabresi PA, Rus H.

Exp Mol Pathol. 2007 Oct;83(2):198-206. Epub 2007 Jul 6.

18.

Insurability of living organ donors: a systematic review.

Yang RC, Thiessen-Philbrook H, Klarenbach S, Vlaicu S, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network.

Am J Transplant. 2007 Jun;7(6):1542-51. Epub 2007 Apr 8. Review.

19.

Reimbursing living organ donors for incurred costs.

Klarenbach S, Vlaicu S, Garg AX.

Am J Transplant. 2007 May;7(5):1308; author reply 1309-10. Epub 2007 Jan 22. No abstract available.

20.

Trends of mortality rates from gastric cancer and colorectal cancer in Romania, 1955-2003.

Valean S, Mircea PA, Oprea L, Frentiu D, Popescu G, Nagy G, Vlaicu S, Damian O.

J Gastrointestin Liver Dis. 2006 Jun;15(2):111-5.

21.

[Smoking habits in Timişoara's teenagers].

Vlaicu B, Petrescu C, Fira-Mlădinescu C, Putnoky S, Suciu O, Vlaicu S, Fira-Mlădinescu O.

Rev Med Chir Soc Med Nat Iasi. 2005 Jul-Sep;109(3):628-32. Romanian.

PMID:
16607762
22.

The direct and indirect economic costs incurred by living kidney donors-a systematic review.

Clarke KS, Klarenbach S, Vlaicu S, Yang RC, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network.

Nephrol Dial Transplant. 2006 Jul;21(7):1952-60. Epub 2006 Mar 22. Review.

PMID:
16554329
23.

Living organ donors face financial barriers: a national reimbursement policy is needed.

Klarenbach S, Garg AX, Vlaicu S.

CMAJ. 2006 Mar 14;174(6):797-8. No abstract available.

24.

Progress and pitfalls in underrepresented minority recruitment: perspectives from the medical schools.

Agrawal JR, Vlaicu S, Carrasquillo O.

J Natl Med Assoc. 2005 Sep;97(9):1226-31.

25.

Serum cholesterol and apoprotein B levels and serum cholinesterase activity in selected hematologic malignancies.

Cucuianu A, Malide D, Petrov L, Patiu M, Vlaicu S, Cucuianu M.

Rom J Intern Med. 1992 Oct-Dec;30(4):261-8.

PMID:
1299417

Supplemental Content

Loading ...
Support Center